I think it is going to be interesting to see how the company handles the 250 event milestone and subsequent top line RRR. What I really hope is that when they report the overall RRR that they also report the RRR of each individual test group, apabetalone + rosuvastatin and apabetalone + atorvastatin. Remember with ASSURE there was a significant difference between these 2 group wrt plaque reduction, if this were to be the same wrt MACE in BETONMACE between the two groups then just the overall RRR will not tell the whole RRR story. Also remember that initially Resverlogix wanted to run this trial with only rosuvastatin + apabetalone.